A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...
There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...
Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on ...
9d
MedPage Today on MSNHigh Price of GLP-1 Agents Tip Cost-Benefit Scale UnfavorablyTirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...
Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...
13d
News-Medical.Net on MSNGLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patientsResearchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...
"Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1." Semaglutide is the active ingredient in Novo's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results